Alliance for Multispecialty Research, LLC | AMR Mobile, AL

Research site

(Unclaimed)

Location

100 Memorial Hospital Drive, Annex Building Suite 3B, Mobile, Alabama, United States of America

Site insights

Top conditions

Top treatments

Cytisinicline

Vicadrostat

Orforglipron

Reloxaliase

Allopurinol

BI 690517

LY3502970

BW-00112

Retatrutide

RGT001-075

Parent organization

This site is a part of Alliance for Multispecialty Research, LLC

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 20 total trials

A Study in Patients with Mixed Dyslipidemia

A Phase 2 in Patients With Mixed Dyslipidemia

Enrolling

Mixed Dyslipidemia

Drug: BW-00112

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting

Chronic Kidney Disease

Overweight

Drug: Orforglipron

Drug: Insulin Glargine

A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults (PISSARRO)

This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF...

Active, not recruiting

Respiratory Syncytial Virus (RSV)

Biological: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE

Biological: HZ/su VACCINE

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People ca...

Begins enrollment this month

Heart Failure

Drug: Placebo matching vicadrostat

Drug: Empagliflozin

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunoge...

Active, not recruiting

Chikungunya Virus Infection

Biological: Placebo booster

Biological: CHIKV VLP vaccine booster

Safety Study of Cytisinicline in Adult Combustible And/or E-cigarette Smokers (ORCA-OL)

Safety assessment of long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks is the main purpose of this study, conducted in the U...

Active, not recruiting

Vaping Cessation

Smoking Cessation

Drug: Cytisinicline

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions (COMO-1)

This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss...

Active, not recruiting

Obesity or Overweight

Drug: Placebo Comparator

Drug: RGT001-075

Locations recently updated

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo